Research Article| Volume 27, ISSUE 8, P1513-1517.e1, September 2012

Cost-Effectiveness of Venous Thromboembolism Prophylaxis With a New Mobile Device After Total Hip Arthroplasty

  • Cost-effectiveness Writing Committee


      Recent comparison (SAFE study) of a mobile, synchronized compression device and low-molecular-weight heparin for prophylaxis of venous thromboembolism showed similar efficacy but significant differences in major bleeding. A model was constructed to evaluate any difference in cost-effectiveness between the 2 therapies incorporating rates and probabilities of major bleeding from the SAFE study with published costs for treating those adverse events. Evaluation of the cost-effectiveness of each therapy was performed and applied to hypothetical patient populations representative of annual health system volume. The model showed a cost-effectiveness advantage of the compression device resulting in a savings of more than $3.69 million in a 10 000-patient cohort. The result was primarily driven by a decrease in the amount of major bleeding, which requires significant health care resources to treat.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal of Arthroplasty
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Merli G.
        Improving venous thromboembolism performance: a comprehensive guide for physicians and hospitalists.
        Hosp Pract (Minneap). 2010; 38: 7
      1. Hospital-Acquired Conditions (HAC) in Acute Inpatient Prospective Payment System (IPPS) Hospitals Department of Health and Human Services.
        (Accessed on 10/17/2011)
        • Pellegrini Jr., V.D.
        • Sharrock N.E.
        • Paiement G.D.
        • et al.
        Venous thromboembolic disease after total hip and knee arthroplasty: current perspectives in a regulated environment.
        Instr Course Lect. 2008; 57: 637
        • Scurr J.H.
        • Coleridge-Smith P.D.
        • Hasty J.H.
        Deep venous thrombosis: a continuing problem.
        BMJ. 1988; 297: 28
        • Trowbridge A.
        • Boese C.K.
        • Woodruff B.
        • et al.
        Incidence of posthospitalization proximal deep venous thrombosis after total hip arthroplasty. A pilot study.
        Clin Orthop Relat Res. 1994; : 203
        • Tremaine M.D.
        • Choroszy C.J.
        • Gordon G.H.
        • et al.
        Diagnosis of deep venous thrombosis by compression ultrasound in knee arthroplasty patients.
        J Arthroplasty. 1992; 7: 187
        • Geerts W.H.
        • Bergqvist D.
        • Pineo G.F.
        • et al.
        Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
        Chest. 2008; 133: 381S
        • Johanson N.A.
        • Lachiewicz P.F.
        • Lieberman J.R.
        • et al.
        Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty.
        J Am Acad Orthop Surg. 2009; 17: 183
        • Vanhoutte P.M.
        • Boulanger C.M.
        • Mombouli J.V.
        Endothelium-derived relaxing factors and converting enzyme inhibition.
        Am J Cardiol. 1995; 76: 3E
        • Allenby F.
        • Boardman L.
        • Pflug J.J.
        • et al.
        Effects of external pneumatic intermittent compression on fibrinolysis in man.
        Lancet. 1973; 2: 1412
        • DiGiovanni C.W.
        • Restrepo A.
        • Gonzalez Della Valle A.G.
        • et al.
        The safety and efficacy of intraoperative heparin in total hip arthroplasty.
        Clin Orthop Relat Res. 2000; : 178
        • Colwell Jr., C.W.
        • Froimson M.I.
        • Mont M.A.
        • et al.
        Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin.
        J Bone Joint Surg Am. 2010; 92: 527
        • Westrich G.H.
        • Jhon P.H.
        • Sanchez P.M.
        Compliance in using a pneumatic compression device after total knee arthroplasty.
        Am J Orthop (Belle Mead NJ). 2003; 32: 135
        • Lachiewicz P.F.
        • Kelley S.S.
        • Haden L.R.
        Two mechanical devices for prophylaxis of thromboembolism after total knee arthroplasty. A prospective, randomised study.
        J Bone Joint Surg Br. 2004; 86: 1137
        • McGarry L.J.
        • Thompson D.
        • Weinstein M.C.
        • et al.
        Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
        Am J Manag Care. 2004; 10: 632
        • PDR Network L
        Red Book—pharmacy's fundamental reference. Thomson Reuters (Healthcare) Inc, Montvale, NJ2010
      2. Medicare RBRVS – The physician's guide: American Medical Association, 2010.

      3. Ingenix. DRG expert—a comprehensive guidebook to the DRG classification system. In: Ingenix, ed.: Ingenix. 2010.

        • Shander A.
        • Hofmann A.
        • Ozawa S.
        • et al.
        Activity-based costs of blood transfusions in surgical patients at four hospitals.
        Transfusion. 2009; 50: 753
      4. The burden of musculoskeletal disease in the United States. In: The burden of musculoskeletal disease in the United States. American Academy of Orthopaedic Surgeons. 2008.

        • Warkentin T.E.
        • Greinacher A.
        • Koster A.
        • et al.
        Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
        Chest. 2008; 133: 340S
        • Greinacher A.
        Heparin-induced thrombocytopenia–pathogenesis and treatment.
        Thromb Haemost. 1999; 82: 148
        • Dolovich L.R.
        • Ginsberg J.S.
        • Douketis J.D.
        • et al.
        A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.
        Arch Intern Med. 2000; 160: 181
        • Gould M.K.
        • Dembitzer A.D.
        • Sanders G.D.
        • et al.
        Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.
        Ann Intern Med. 1999; 130: 789
        • Kapoor A.
        • Chuang W.
        • Radhakrishnan N.
        • et al.
        Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
        Pharmacoeconomics. 2010; 28
        • Shorr A.F.
        • Sarnes M.W.
        • Peeples P.J.
        • et al.
        Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
        Am J Health Syst Pharm. 2007; 64: 2349